What are the side effects of Wegovy?
Wegovy is an effective weight-loss medicine, but as with all medicines, side effects may occur. In this blog, you can read about the side effects that may occur, when they typically occur, and how Goodweigh supports you in ensuring a safe and comfortable treatment journey. If you would first like to read more about how this medicine works, you can find more about Wegovy on our product page.
Which side effects occur most frequently?
The most common side effects of Wegovy are gastrointestinal symptoms. Nausea is by far the most commonly reported complaint: the STEP 1 study shows that over 44% of users suffered from this to some degree, compared with 16% in the placebo group. Diarrhoea occurred in approximately 30% of participants, vomiting in 25% and constipation in 24%. In addition, some users report headaches and fatigue, particularly in the first few weeks of treatment. Hair loss occurs in approximately 2.5% of users. This almost always involves telogen effluvium, a temporary form of hair loss in response to physical changes, which usually resolves on its own. A slight increase in heart rate has also been observed, averaging approximately three extra beats per minute.
When do most side effects occur?
Side effects are most noticeable in the first few weeks of treatment, and this is no coincidence. Wegovy is started at a low dose of 0.25 mg per week and is then increased every four weeks until the maintenance dose of 2.4 mg per week is reached. With each new dose increase, the body may again react temporarily with nausea or other gastrointestinal discomfort. Safety studies show that this gradual titration schedule is specifically designed to make the side effects as tolerable as possible. For most people, the discomfort subsides noticeably after a few days to weeks.
Are there also rare or serious side effects?
Although the majority of users experience only mild to moderate symptoms, rare but serious side effects have also been reported. Clinical research published in The Lancet shows that acute pancreatitis, gallstones (cholelithiasis) and cholecystitis can occur, albeit rarely. In exceptional cases, acute kidney failure has been reported, almost always as a result of severe dehydration due to persistent vomiting or diarrhoea. In people who are also using insulin, there is an increased risk of severe hypoglycaemia. Anaphylaxis and intestinal obstruction are extremely rare, but are mentioned in the official product information from the European Medicines Agency. Wegovy is contraindicated in people with a history of pancreatitis, severe kidney or liver failure, type 1 diabetes and during pregnancy.
How can mild side effects be alleviated?
Mild side effects are bothersome, but for most people they are easy to manage with a few practical adjustments. Eating smaller meals, chewing more slowly and avoiding fatty or strongly spiced foods helps with nausea. Read our page on what is best to eat whilst taking Wegovy for further advice. It is important to drink enough fluids, especially if you have diarrhoea or are vomiting, to prevent dehydration. Constipation usually responds well to a diet higher in fibre and exercise. It is also a good idea to schedule your injection for a fixed time each week, so that any discomfort becomes predictable and you can plan for it.
What should you do if you experience serious symptoms?
If you have persistent, severe abdominal pain radiating into your back, you must stop injecting immediately and contact a doctor or your own GP. This also applies to symptoms of a serious allergic reaction, such as swelling of the lips, tongue or throat, or signs of dehydration. Please also read our page on the safe use of Wegovy for an overview of situations where you should take action. If in doubt, it is always wise to contact your healthcare provider, even outside of your regular check-ups.
Do the side effects go away on their own?
For the vast majority of users, the answer is yes. Researchers conclude that gastrointestinal discomfort with Wegovy is typically temporary and is most severe at the start or following a dose increase. Once the dose is stable, the body adjusts to the medicine, and the discomfort subsides significantly in most people. A long-term study published in Nature Medicine shows that people who stick with the treatment also achieve the greatest weight loss, which emphasises that in most cases it is worth persevering.
How does Goodweigh help with Wegovy side effects?
At Goodweigh, you are not on your own. Our doctors and coaches actively support you throughout your treatment, even if you experience side effects. Through Goodweigh’s guidance, you have access to personalised advice on dose adjustments, lifestyle and nutrition. If a side effect persists or feels too burdensome, we will decide together whether to postpone the dose increase or adjust the approach. This is precisely the difference compared to treatment without guidance: there is always someone available to help you find a solution.
Get started safely with Wegovy with guidance from Goodweigh
For many people, side effects are part of the initial phase of treatment, but they are manageable and temporary. The gradual titration schedule, combined with the right lifestyle advice and active medical guidance, means that most people tolerate the treatment well. If you have questions about the differences compared to a similar product, please also read our article on the difference between Ozempic and Wegovy. At Goodweigh, we guide you step by step so that you can safely and comfortably work towards a healthier weight.
Referencer
- Wilding, J. P. H., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. https://pubmed.ncbi.nlm.nih.gov/33567185/
- Smits, M. M., & Van Raalte, D. H. (2021). Safety of Semaglutide. Frontiers in Endocrinology. https://pubmed.ncbi.nlm.nih.gov/34305810/
- Davies, M., et al. (2021). Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2). The Lancet. https://pubmed.ncbi.nlm.nih.gov/33667417/
- Chao, A. M., et al. (2023). Semaglutide for the treatment of obesity. Trends in Cardiovascular Medicine. https://pubmed.ncbi.nlm.nih.gov/34942372/
- Ryan, D. H., et al. (2024). Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial. Nature Medicine. https://pubmed.ncbi.nlm.nih.gov/38740993/
- Europees Geneesmiddelenbureau. (z.d.). Wegovy: EPAR-productinformatie. https://www.ema.europa.eu/nl/documents/product-information/wegovy-epar-product-information_nl.pdf
Dit sidste vægttabsprogram
Forandring dit liv med Goodweigh-vægttabsprogrammet, der er udviklet til varig succes.
.avif)

